{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"48.6","value":"22.83"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"36.5","value":"24.84"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"45.5","value":"19.38"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"description":"the best response designation over the study as a whole, recorded between the date of first dose and the last efficacy assessment prior to subsequent therapy.\n\nMeasured in Complete Remission and Partial Remission","dispersionType":"Full Range","groups":[{"description":"3mg/kg of nivolumab","id":"OG000","title":"Nivolumab Monotherapy (Expansion)"},{"description":"3 mg/kg of nivolumab and\n\n1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W","id":"OG001","title":"Nivolumab + Ipilimumab"},{"description":"3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W","id":"OG002","title":"Nivolumab + Lirilumab"}],"paramType":"MEDIAN","populationDescription":"All Responding participants (Complete Response and Partial Response) with available measurements (excluding Multiple Myeloma (MM) Group)","reportingStatus":"POSTED","timeFrame":"Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to approximately 37 months Nivo Liri: approximately up to 4 years 1 month","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"Months"}